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diagnosis of osteoporosis between January 1 and June
30, 1999 and 2 pharmacy claims for an estrogen or
SERM were selected from the PharMetrics Integrated
Outcomes Database. Patients were excluded if they had
less than 6 months of continuous enrollment following
the first (index) prescription claim for an estrogen or
SERM or received other drugs for osteoporosis, such as
bisphosphonates or calcitonin-salmon. The frequency of
of hip, vertebral, forearm/wrist or other fracture and/or
related surgical procedures and osteoporosis-specific
charges were assessed over the 6-month period following
the index prescription. RESULTS: 252,892 patients met
the selection criteria, including 245,650 treated with es-
trogen and 7,242 with SERMs. The estrogen cohort was
significantly younger than the SERM cohort (mean age:
54.3 vs. 59.0 years, p  0.001) and had less frequent
fractures/surgical procedures (1.0% vs. 1.6%, p  0.001).
The SERM group had higher mean osteoporosis-related
pharmacy ($309 vs. $106) and medical charges ($73 vs.
$29) resulting in a total charge difference of $247 (p 
0.001). Stratified analyses indicated that the SERM co-
hort had consistently higher mean charges across all age
ranges compared to the estrogen cohort. CONCLUSION:
In this initial cost comparison between SERM and estro-
gen therapy for osteoporosis, short-term (6-month) os-
teoporosis-related charges were significantly higher in the
SERM group primarily due to the difference in drug
costs. Longer-term studies are required to examine all of
the costs associated with these therapies.
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OBJECTIVE: To compare rheumatoid arthritis (RA)
treatment charges with a cyclooxygenase-2 specific inhib-
itor (COX-2) versus a non-steroidal anti-inflammatory
drug (NSAID) therapies in a managed care population.
METHODS: Patients with a diagnosis of RA between
January 1 and June 30, 1999 who had prescriptions for
COX-2s or NSAIDs were selected from the PharMetrics
Integrated Outcomes Database. Patients were excluded if
they had osteoarthritis or did not have 6 months of con-
tinuous enrollment following the first (index) COX-2 or
NSAID pharmacy claim. COX-2 and NSAID-treated
groups were compared on their demographics, comorbid-
ities, and total RA-specific charges during the 6 month
follow-up period RESULTS: A total of 5,261 patients
met the patient selection criteria, including 668 who re-
ceived COX-2 and 4,593 who received NSAID. The
COX-2 group was older (53.7 versus 49.6 years, p 
0.0001) on average and more likely to have at least one
comorbidity (46.0% vs. 31.9%, p  0.001) compared to
the NSAID group. They also had higher RA-related phar-
macy ($914 versus $636) and medical charges ($611 ver-
sus $566). Total mean charges for the COX-2 cohort
were $323 higher (p  0.019) than the NSAID cohort.
CONCLUSION: In this initial cost comparison between
COX-2s and NSAIDs, the mean charge for a 6-month pe-
riod with COX-2s was 27% higher than with NSAIDs,
mainly due to higher pharmacy charges. Longer-term
studies are required to examine whether the higher acqui-
sition costs of COX-2 are offset by savings in the costs of
treating gastrotoxicity.
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BACKGROUND: Rheumatoid arthritis (RA) leads to phys-
ical and psychosocial functional disabilities affecting pro-
ductivity of patients in their daily activities. OBJECTIVE:
to evaluate the impact of early RA on productivity.
METHODS: Baseline data was analyzed from the Study
of New Onset Rheumatoid Arthritis (S.O.N.O.R.A.SM),
a five-year prospective, longitudinal, inception-cohort
study to document long-term functional, clinical, and hu-
manistic outcomes and patterns of treatment in patients
with new onset RA. Telephone interviews were per-
formed by trained interviewers to collect data on employ-
ment status, annual household income (AHI) and pro-
ductivity at work and normal activities, outside of paid
job (NAOPJ), including absenteeism over the past 4
months, reason for absenteeism, and effectiveness at
work and NAOPJ when working with arthritis symptoms
(AS). RESULTS: One hundred thirty one patients com-
pleted the baseline survey. Mean age was 56  15 years;
78% were female; 82% were Caucasian. Employment
status reported was full-time (52%), part-time (2%), re-
tired (26%), and other (20%). AHI were $50,000
(63%), $50,000–74,999 (17%), $75,000 (18%), and
2% refused to provide AHI. Ninety-one percent of pa-
tients were employed at a paid job. The mean absentee-
ism at work and NAOPJ were 4.3 days (SE  1.1) and
25.9 days (SE  3.3), respectively. Of the participants re-
porting absenteeism, 40% and 69% reported that the
majority of absenteeism was due to AS for work and
NAOPJ, respectively. Compared to their normal perfor-
mance, patients were 78% and 64% as effective when
working with AS at work and NAOPJ, respectively.
CONCLUSION: Despite new onset of RA in this popula-
tion, negative impact on productivity was observed. A
greater decline in productivity was reported for NAOPJ.
This may imply that NAOPJ is compromised before
work activities in early RA patients. Five-year follow-up
of this population will provide further insight on produc-
tivity changes and the economic burden associated with
progressive disease.
